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Objective. Conventional surgery for varicose veins due to small saphenous reflux is associated with high recurrence rates
(up to 50%), many resulting from inadequate surgery. This prospective audit examines the safety and efficacy of EVLA in
the treatment of this.
Method. 65 patients (68 limbs) with varicosities due to primary or recurrent sapheno-popliteal junction (SPJ) and small
saphenous vein (SSV) reflux underwent out-patient EVLA (810 nm diode laser). The SSV was ablated from mid-calf to the
SPJ. Symptomatic improvement (Aberdeen Varicose Vein Severity Score [AVVSS]), time to return to normal activity, post-
EVLA analgesic requirements, and complications were recorded.
Results. Duplex ultrasound follow-up (median 6-months) confirmed abolition of SPJ/SSV reflux in all limbs following
a median total laser energy delivery of 1131J (IQR 928-1364) at an energy density of 66.3 Joules/cm (IQR 54.2e71.6).
AVVSS improved from 15.4 (IQR 11.8e19.7) to 4.6 (IQR 3.2e6.7) at three months (p< 0.001). Median analgesia re-
quirement was 3 days (23% [15/65] patients required none) and the median time to normal activity was 0 (0e4) days (65%
[42/65] returning to normal daily activity immediately). There were no instances of skin burns or DVT but 3 patients
(4.4%) developed transient cutaneous numbness (sural nerve). 98% (64/65) patients would undergo EVLT again.
Conclusions. EVLA abolished SPJ/SSV reflux in all limbs. This is likely to be more effective than conventional surgery,
although long-term follow up is required. Data from a randomised control trial would be desirable.
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The standard treatment for varicose veins associated
with small saphenous reflux is ligation of the sapheno-
popliteal junction (SPJ) with or without stripping of
the small saphenous vein (SSV) under general anaes-
thesia. However recurrence rate following surgery
may be as high as 50%1 at 3 years. In many instances
this is the result of inaccurate ligation of the SPJ.
In addition neovascularisation, which is the common-
est cause for recurrence following sapheno-femoral
ligation and stripping2,3 may have a role. The fre-
quency with which this occurs following SSV surgery
has not been investigated but when present it
allows further reflux into the SSV, which is often still
present.
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new, minimally invasive technique that was primarily
developed to treat varicose veins due to sapheno-
femoral (SF) and great saphenous vein (GSV) reflux
with high success rates (88e100%).4e6 It is an outpa-
tient procedure which is performed under tumescent
local anaesthesia. It has been suggested that the laser
energy creates steam bubbles from blood which cause
thermal injury to the vein wall resulting in damage to
the endothelial and sub-endothelial tissues.7 Alterna-
tively direct contact between the laser fibre and the
vein wall may be responsible for the thermal injury.
Aside from its anaesthetic function the tumescent
anaesthesia absorbs heat and prevents injury to the
surrounding tissues. Further it compresses the vein
around the laser fibre. Although the temperature at
the laser fibre tip exceeds 720 C, that of surrounding
tissue reaches a median of 34.5 C (maximum 43.3 C)
when using a 12 W power source.8e10 Since irrevers-
ible nerve damage only occurs at temperatures ex-
ceeding 45 C the close proximity of these to the SSV
should not be a cause for concern. That EVLA mayrved.
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flux is suggested by the poor results from surgery, the
accurate visualisation of the SPJ with ultrasound
during EVLA, allowing ablation of the SSV from this
point distally, and the possibility that laser ablation
reduces the risk of neo-vascularisation.
Methods
Patients
Sixty-five patients (68 limbs) attending the venous
clinics at either the General Infirmary at Leeds
(n¼ 42) and or the BUPA Hospital, Leeds (n¼ 23) be-
tween Nov 2004eJan 2006 with symptomatic varicosi-
ties due to SPJ/SSV reflux underwent SSV EVLA.
Suitability for the procedure depended upon
a 10 cm relatively straight segment of SSV immedi-
ately distal to the SPJ, an absence of significant varicos-
ities arising within 5 cm of the SPJ and a distal SSV of
3 mm diameter at the intended cannulation site.
Demographic details are shown in Table 1. Primary
varicose veins were present in 52 limbswhilst previous
SPJ ligation had been performed in 16 limbs. Using
the CEAP classification, determined by a consultant
vascular surgeon or an experienced surgical trainee,
the maximum grading was C2 in 46 patients, C3 in 8,
C4 in 12 and C5 in 2. All C2 patients complained of
aching and/or pruritis.
Laser technique
Under ultrasound guidance the SSV was cannulated
in mid-calf or a little higher if there was a relatively
short segment of straight SSV. A guide wire was
passed proximally into the popliteal vein and a 5FG
Table 1. Patient demography and disease severity scores
(maximum ‘‘C’’ score for each patient)
Number patients (n) 65 (68 limbs)
Median age (range) 48 years (28e82)
Male: Female 22: 43
BMI, Median (IQR) 25.1 (22.4e28.3)
Vein Diameter*, Median (IQR) 6.2 mm (5.1e7.6)
CEAP classification:
C2 Varicose veins n¼ 46 (68%)
C3 Oedema n¼ 8 (11%)
C4 Skin changes n¼ 12 (18%)
C5 healed ulcer n¼ 2 (3%)
C6 active ulcer n¼ 0
Ep primary n¼ 68 (100%)
Es secondary n¼ 0
As superficial veins n¼ 68 (100%)
Pr reflux n¼ 68 (100%)
CEAP score: Clinical, Etiology, Anatomy, Pathology.
* Maximum diameter measured with patient standing.catheter was positioned under ultrasound control
1 cm distal to the SPJ. Relatively larger volumes
(compared to greater saphenous vein EVLA) of peri-
venous tumescent local anaesthesia (0.1% lignocaine,
150e200 ml) were infiltrated along the vein under
ultrasound guidance with a greater proportion (50e
60 ml) of this is used in the popliteal fossa to eliminate
the possibility of thermal nerve injury. A laser fibre
connected to an 810 nm diode laser source was
inserted via the catheter and then gradually with-
drawn so that 5e6 pulses of laser energy (12 Watts
power, 1 second pulses, 1 second intervals) were
delivered/cm vein (60e72 Joules/cm).
Following treatment a non-stretch compression
bandage was applied to the limb for 1 week followed
by a class 2 support stocking for a further week.
Patients were prescribed 50 mg diclofenac sodium
tds for 3 days to reduce inflammatory changes in
the SSV and encouraged to resume their daily activi-
ties (including work) as soon as possible.
Data collection and follow-up
Pretreatment data collection included clinical assess-
ment of the varicose veins (CEAP clinical stage), com-
pletion of the AVVSS questionnaire and measurement
of maximum SSV diameter on standing. Details of the
laser energy used and the length of vein treated were
also recorded. Following treatment patients kept
an analgesic diary for one week and underwent
clinical and duplex scan assessments at 6 weeks, 3 mon-
ths and6months todeterminewhether the SSVhadbeen
successfully ablated.
Specifically, ultrasound examination determined if
the SSV remained visible and if so its patency was
assessed on the basis of compressibility and visible
colour flow following a calf squeeze. If SSV flow
was present venous reflux was assessed using both
Doppler waveform analysis and colour flow imaging.
Finally, the deep veins were examined for evidence of
deep vein thrombosis.
Clinical examination at 6 weeks was used to assess
the extent of any residual varicose veins. If these were
of cosmetic concern they were treated by foam sclero-
therapy (1e2 ml 0.5% sodium tetradecyl sulphate,
mixed with 3e6 ml of air using a 3-way tap) on
patient request. At subsequent clinical review the de-
velopment of recurrent varicosities was determined.
The AVVSS questionnaire was repeated at 3 months.
All data including the ultrasound findings were
collected by a team of 2 consultant vascular sur-
geons and 2 research fellows who had appropriate
ultrasound training.Eur J Vasc Endovasc Surg Vol 33, May 2007
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bitis, bruising, pigmentation, skin burn, DVT) was
maintained and the presence or absence of cutaneous
numbness determined by direct question and mapped
by clinical examination when reported. Finally
patients were asked whether they would undergo
laser ablation again and if they would recommend
the procedure to a friend.
Statistical methods
The AVVSS before and after laser ablation were com-
pared using aWilcoxon test. For paired data. A p value
of <0.05 was considered significant.
Results
A median of 17 cm (IQR: 12e20) of SSV was ablated
using a total energy of 1131 J (IQR: 928e1364) delivered
at an energy density of 66.3 Joules/cm (IQR 54.2e71.6).
The time taken return to normal daily activity was
a median (IQR) of 0 (0e4) days with 42/65 (65%)
patients doing so straightaway. Analgesics were re-
quired for 3 (0e14) days. Although diclofenac sodium
was prescribed for 3 days 15/65 (23%) patients did
not take any painkillers. 12/68 (18%) limbs received












Fig. 1. Pre and post treatment Aberdeen Varicose Vein
Severity Score (AVVSS) in patients undergoing small
saphenous vein laser ablation. Thick and thin horizontal
lines indicate the median and range. The boxes represent
inter-quartile range.
Eur J Vasc Endovasc Surg Vol 33, May 2007The median (IQR) pre-treatment AVVSS was 15.4
(11.8e19.7) compared to 4.6 (3.2e6.7) 3-months post
treatment (Fig. 1). This improvement was highly
significant (p< 0.001). Finally 64/65 (98%) patients
would choose laser treatment again if needed.
Although not specifically recorded, minor bruising
along the line of the SSV was reported by most
patients. However this had disappeared by the time
of the six week assessment. Although some minor
pigmentation was present in a minority of limbs at
this time this had resolved in all patients by 3 months.
No skin burns occurred.
Symptomatic superficial ‘‘phlebitis’’ of the SSV was
documented in 3/68 (4.4%) limbs and was treated
with a further course of diclofenac sodium 50 mg
tds for as long as required. There was no evidence
of deep vein thrombosis on either clinical or ultra-
sound examination in any patient.
Transient numbness in the distribution of the sural
nerve was reported in 3/68 (4.4%) limbs at initial
follow-up and this was confirmed by objective neuro-
logical examination. It resolved by 6 months in all
patients. No other neurological symptoms or signs
were documented.
Ultrasound examination confirmed complete occlu-
sion of the small saphenous vein to the level of
sapheno-popliteal junction in all limbs (68/68, 100%)
at 6 and 12 weeks. Fourty-eight limbs (46 patients)
have completed at least six months follow up. The
SSV was no longer visible in 42 limbs (88%), iso-echoic
in 4 representing simple occlusion and hyperechoic
(obliteration/fibrosis) in 2.
In the 12 limbs receiving sclerotherapy no further
varicosities developed by 6 month follow-up and
none of the patients (56 limbs) who did not require
adjuvant sclerotherapy at 6 weeks have requested it
to date.
Discussion
Successful treatment of small saphenous varicosities
depends upon abolition of sapheno-popliteal and
small saphenous vein reflux. The former is tradition-
ally achieved by sapheno-popliteal ligation although
stripping of the small saphenous vein is controversial
as it may be associated with sural nerve injury. Accu-
rate ligation of the sapheno-popliteal junction can be
technically demanding because of variability in its an-
atomical location and the relatively poor exposure of
the popliteal vein and its branches afforded by a
cosmetically acceptable wound. Although accurate
ligation is facilitated by pre-operative ultrasound
marking of the junction more than 50% of patients
617Endovenous Laser Ablation of Small Saphenous Veinmay develop recurrent varicose veins, often as a result
of inadequate surgery.1
Conventional varicose vein surgery may also be
associated with significant morbidity. Although usu-
ally minor (wound problems, cutaneous neuro-sensory
loss) it may delay return to normal activity and
employment. Further, more serious complications
may occur during sapheno-popliteal ligation with 12
cases of foot drop due to nerve injury being recorded
in the NHS Litigation Authority database between
1995e2003.
In view of these drawbacks the newer minimally in-
vasive methods of treating superficial venous incom-
petence are of interest. Endovenous laser ablation of
the great saphenous vein was described by Min et al.
in 2001.5 This and subsequent reports11e15 have con-
firmed initial success for the technique in 90e100% of
patients with permanent abolition of reflux in up to
98% at a maximum 5 years follow up.16 Similar results
are reported for radiofrequency ablation (RFA) with
a multi-centre study reporting that 85% of great saphe-
nous veins were obliterated at 2 years.17 Other series
report occlusion rates of 88e100% at similar follow-
up.18e20 Although efficacy for EVLA and RFA appear
similar the cost of disposables for the latter is greater
and treatment times longer. Thus in our unit we have
adopted EVLA as our preferred technique.
Foam sclerotherapy of truncal veins is also gaining
popularity and has the advantage of significantly
lower cost. However there is some concern about
the durability of the technique with GSV occlusion
rates of 90% at 28 days but only 81% at 3 years.21,22
In contrast to great saphenous vein ablation there
has been concern about the possible risk of nerve injury
in the popliteal fossa during laser therapy for small
saphenous vein reflux. The temperature at the tip of
the laser fibre may reach 720 C and although tumes-
cent anaesthesia reduces heat transfer to adjacent tissue
irreversible nerve injury may occur at temperatures
above 45 C. In a previous study measurements
adjacent to the great saphenous vein have confirmed
that following adequate infiltration of tumescent an-
aesthesia the perivenous temperature reaches amedian
of 34.5 C and thus nerve injury should be avoided.10
The present study has confirmed that laser ablation
of the small saphenous vein is both effective and safe.
Although 3patients developed temporaryparaesthesia
in the distribution of the sural nerve this resolved
within 6months. Therewas no evidence of othermotor
or sensory nerve injury. Similarly there were no
instances of skin burns nor of other serious complica-
tions such as deep vein thrombosis. Further, the small
saphenous vein was successfully ablated from the
sapheno-popliteal junction in all patients withspontaneous regression of associated varicosities in
52/68 (76%) limbs. In the 16 limbs with some residual
varicosities delayed (6 weeks) foam sclerotherapy
was performed in 12 (18%). No further treatment was
required in 4 limbs in which symptoms had resolved
and any remaining varicose veins were of no concern.
Successful ablation of the small saphenous veinwas as-
sociatedwith a significant reduction in symptomsever-
ity scores and a rapid return to normal activity (65% of
patients doing so immediately).
Although not the primary focus of this study we
also assessed the proportion of patients who were
suitable for SSV EVLA. Thus 50/69 (72%) and 15/22
(69%) of patients with either primary or recurrent
varicose veins were suitable for EVLA.
Two other small studies have also reported similar
efficacy for SSV ablation using EVLA (occlusion rates
95%, 97%)23,24 although neither reported the impact of
this on symptom relief or the need for subsequent
sclerotherapy. Similarly, post treatment morbidity
was not described.
In summary, this study has confirmed the safety
and efficacy of endovenous laser ablation in the treat-
ment of small saphenous varicosities. Given the vari-
able results of sapheno-popliteal ligation ultrasound
guided laser treatment is likely to prove more success-
ful than conventional surgery provided that the dura-
bility of the procedure is similar to that reported for
great saphenous vein laser therapy. Long term follow
up is awaited.
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